Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.
The buy-in from other companies into the space has been far larger.
Asian markets have been spooked by the fall of these mighty executives.
Any way you slice it, rapid reorganization of Flipkart only months after its purchase does not reflect well on Walmart.
Jim Cramer says ExxonMobil's $2.2 billion bid for InterOil isn't that much money for Exxon, but is 'anything but conservative.'